Trial Profile
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Navtemadlin (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 17 Feb 2024 The procedures of Echocardiography, Biospecimen Collection and one Marrow Aspiration and Biopsy have been added.
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.